[April 14, 2014]

Research and Markets: Global Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/sm6dww/recombivax_hb) has announced the addition of the "Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Recombivax HB [Hepatitis B Vaccine (Recombinant)] is Merck's monovalent vaccine that protects children, adolescents, and adults against acute and chronic infections caused by all identified strains of HBV. Merck's vaccine was the first recombinant vaccin for HBV to be widely commercialized. Upon its approval and launch in the US in 1986, Recombivax HB began to replace the first-generation, human plasma-derived HBV vaccines as the preferred treatment option for active immunization against acute and chronic HBV infection (CDC, 2012a; FDA, 1987).

Scope

• Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Recombivax HB including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Recombivax HB for top eight countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, UK, Japan and Canada.

Key Topics Covered:

1. Tables & Figures
2. Introduction
3. Disease Overview
4. Vaccination Recommendations and Coverage Rates
5. Competitive Assessment
6. Recombivax HB
7. Appendix

Visit http://www.researchandmarkets.com/research/sm6dww/recombivax_hb

[ Back To TMCnet.com's Homepage ]